Global Epithelial Ovarian Cancer Market, Global Epithelial Ovarian Cancer Market Report, Global Epithelial Ovarian Cancer Market Trends, Global Epithelial Ovarian Cancer Market Size

Epithelial Ovarian Cancer Market Forecast: What to Expect by 2029

November 26, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

#What Is The Projected Market Size Of The Epithelial Ovarian Cancer Market By 2029?

The epithelial ovarian cancer market has seen substantial growth over recent years. It is projected to expand from $2.08 billion in 2024 to $2.41 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 16.0%. This historical growth can be attributed to increasing demand for personalized cancer treatments, a rise in global healthcare expenditure, a growing demand for minimally invasive surgeries, the rising number of ovarian cancer survivors, an increasing demand for gene therapies, and a heightened demand for palliative care services.

The market size for epithelial ovarian cancer is anticipated to experience significant expansion in the upcoming years. It is projected to reach $4.36 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 16.0%. This projected growth stems from several factors, including the increasing occurrence of ovarian cancer, an aging demographic, enhanced awareness of ovarian cancer, a rise in research funding for cancer, and growing government initiatives against cancer. Prominent trends for this forecast period involve technological improvements in medical imaging, the introduction of advanced molecular diagnostic tools, strategic alliances between pharmaceutical companies, the quick adoption of AI and machine learning in diagnostic processes, and the expanding utilization of robotic surgeries.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20778&type=smp

Which Major Market Drivers Are Shaping The Future Of The Epithelial Ovarian Cancer Market?

The expanding occurrence of ovarian cancer is anticipated to stimulate the expansion of the epithelial ovarian cancer market in the coming years. This form of cancer originates in the ovaries, predominantly impacting the epithelial cells found on their surface. The rise in ovarian cancer cases is largely attributed to an older demographic, enhanced public awareness, and improved diagnostic capabilities, in addition to contributing genetic and lifestyle elements. Treatment for epithelial ovarian cancer is crucial for tackling this most frequent and aggressive type, aiming to target cancerous cells to enhance survival rates and patient prognoses. As an illustration, figures from February 2024, provided by the World Ovarian Cancer Coalition, a Canada-based non-profit organization, project that by 2050, the worldwide total of women diagnosed with ovarian cancer will likely surge by over 55%, reaching 503,448. Concurrently, annual fatalities from ovarian cancer are anticipated to climb to 350,956, representing a nearly 70% increase compared to 2022. Consequently, the growing incidence of ovarian cancer is set to propel the epithelial ovarian cancer market into the future.

What Are The Segment Types Shaping The Epithelial Ovarian Cancer Market?

The epithelial ovarian cancermarket covered in this report is segmented –

1) By Type Of Treatment: Chemotherapy; Targeted Therapy; Immunotherapy; Hormonal Therapy; Surgery

2) By Drug Class: Platinum-based Chemotherapy Drugs; Poly(ADP-ribose) Polymerase Inhibitors; Bevacizumab; Chemotherapeutic Agents

3) By Stage Of Cancer: Early Stage; Advanced Stage

4) By Diagnosis Method: Imaging; Biopsy; Blood Tests

5) By End User: Hospitals; Clinics; Diagnostic Laboratories

Subsegments:

1) By Chemotherapy: Platinum-Based Chemotherapy; Non-Platinum Chemotherapy; Combination Chemotherapy

2) By Targeted Therapy: Monoclonal Antibodies; PARP Inhibitors; Angiogenesis Inhibitors; Other Targeted Agents

3) By Immunotherapy: Checkpoint Inhibitors; Cancer Vaccines; Adoptive T-Cell Therapy

4) By Hormonal Therapy: Selective Estrogen Receptor Modulators (SERMs); Aromatase Inhibitors; Progestins

5) By Surgery: Debulking Surgery; Oophorectomy; Hysterectomy; Other Surgical Procedures

Which Trends Are Impacting The Epithelial Ovarian Cancer Market?

Major companies operating in the epithelial ovarian cancer market are prioritizing the creation of novel therapeutic options, including FRa-directed antibody-drug conjugates (ADCs). These innovative treatments are designed to specifically target folate receptor-alpha, which is overexpressed on cancer cells, facilitating the delivery of powerful cytotoxic agents while minimizing adverse effects on healthy tissues. An FRa-directed antibody-drug conjugate (ADC) functions as a targeted cancer therapy by linking an antibody specific to the folate receptor-alpha (FRa) to a cytotoxic drug, ensuring the drug is directly delivered to cancer cells expressing this particular receptor. For example, in November 2024, AbbVie Inc., a US-based biopharmaceutical company, obtained European Commission approval for ELAHERE (mirvetuximab soravtansine), a targeted treatment intended for adult patients with folate receptor-alpha (FRa) positive, platinum-resistant, high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer. ELAHERE presents a new and effective treatment alternative for patients who have previously undergone up to three systemic regimens. It targets a biomarker found in approximately one-third of ovarian cancer patients, thereby improving survival rates and enhancing their quality of life. The approval further includes a companion diagnostic tool for identifying appropriate patients.

Who Are The Major Companies Operating In The Epithelial Ovarian Cancer Market?

Major companies operating in the epithelial ovarian cancer market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline plc, Eli Lilly and Company, Boehringer Ingelheim GmbH, Merck KGaA, Siemens Healthineers AG, Quest Diagnostics Incorporated, Eisai Co. Ltd., Genentech Inc., Qiagen N.V., Myriad Genetics Inc., Zymeworks Inc., Novogen Limited, Karyopharm Therapeutics Inc., Clovis Oncology Inc., ImmunoGen Inc., Fujirebio Diagnostics Inc., Vivesto AB

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/epithelial-ovarian-cancer-global-market-report

What Are The Regional Market Dynamics Impacting The Epithelial Ovarian Cancer Industry?

North America was the largest region in the epithelial ovarian cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the epithelial ovarian cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Epithelial Ovarian Cancer Market Report:

https://www.thebusinessresearchcompany.com/customise?id=20778&type=smp

Browse Through More Reports Similar to the Global Epithelial Ovarian Cancer Market 2025, By The Business Research Company

Ovarian Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/ovarian-cancer-drugs-global-market-report

Polycystic Ovarian Syndrome Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/polycystic-ovarian-syndrome-treatment-global-market-report

Ovarian Cancer Drugs Market 2025

https://www.thebusinessresearchcompany.com/report/ovarian-cancer-drugs-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795